Last updated: 2026-09-04 17:04:40. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Niki BioSolutions, Inc. (NIKI) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $6,30, with a market capitalisation of $5,38M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $6,09 to $12,24. This page covers its latest market performance, valuation, price trends and company information.
$5,38M | |
$7,15 | |
$12,24 | |
$6,09 | |
$6,51 | |
3,98M | |
-- | |
-- | |
$12,24 | |
$6,09 | |
-- | |
-- |
Niki BioSolutions, Inc. (NIKI) is currently trading at $6,30 as of 2026-09-04 17:03:00, down 3,16% ($0,21) from the previous close of $6,51
During today's regular trading session, NIKI has traded between $6,09 and $12,24, with a trading volume of 3,98M shares. The current price is near the lower end of today's range.
Over the past seven days, Niki BioSolutions, Inc. (NIKI) moved from $6,69 to $6,30, representing a decline of 5,80% ($0,39).
The stock traded between $6,09 and $9,48 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 608,89 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 3,4%
NIKI is currently trading at $6,30, placing it 3,4% of the way from its 52-week low of $6,09 to its 52-week high of $12,24. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Niki BioSolutions Inc, formerly Aptorum Group Ltd is a clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Its project pipeline includes SACT-1, a repurposed drug for the treatment of neuroblastoma, and ALS-4, a small molecule for the treatment of bacterial infections caused by Staphylococcus aureus, including but not limited to Methicillin-resistant Staphylococcus aureus (MRSA).
| Employees | 2 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Niki BioSolutions, Inc. (NIKI) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.